Understanding Eosinophilic Granulomatosis with Polyangiitis
Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare and complex autoimmune disease that primarily affects individuals with a history of asthma and elevated eosinophil levels. This condition is highly variable in its presentation, manifesting in multiple ways that can make diagnosis challenging. Common symptoms include severe asthma, chronic sinusitis with nasal polyps, and neuropathy, which may cause pain, numbness, or weakness in the arms and legs. Additionally, EGPA can affect internal organs, leading to complications such as gastritis, heart failure, and kidney disease, specifically glomerulonephritis.
One of the key characteristics of EGPA is its unpredictability. Patients may experience different symptoms at various stages of the disease, making it difficult to recognize early on. Some individuals may initially present with respiratory symptoms, while others might develop neurological or gastrointestinal issues before the underlying condition is identified. Because eosinophils play a central role in the disease process, treatments that target these immune cells have been developed. Biologic therapies such as Fasenra (benralizumab) and Nucala (mepolizumab) are monoclonal antibodies designed to reduce eosinophil levels, thereby helping to control inflammation and alleviate symptoms.
Due to the complexity and variability of EGPA, early recognition and appropriate treatment are essential to managing the disease effectively. A multidisciplinary approach involving pulmonologists, rheumatologists, and other specialists is often necessary to address the diverse symptoms and prevent severe complications. With advancements in targeted therapies, patients with EGPA have more treatment options that can improve their quality of life and disease outcomes.
If you need to book an appointment for your allergies or asthma, you can book your appointment online, or call (212) 247-7447.